Beyond traditional monitoring of kidney transplant recipients, donor derived-cell free DNA may permit early identification of graft damage.

A blood test measuring donor‑derived cell‑free DNA (dd‑cfDNA) is emerging as a sensitive tool for early detection of kidney transplant rejection, potentially reducing the need for invasive biopsies.

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Study: Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Image Credit: 3dMediSphere / Shutterstock In a recent study published in the ...

Researchers have identified a rare T cell–dendritic cell interaction that drives liver inflammation and fibrosis, confirmed in both mice and human tissue. In parallel, a new AI-powered blood test can ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. The agency provided gross pay records ...